Isolated Pancreatic Myeloid Sarcoma Associated with t(8;21)/RUNX1-RUNX1T1 Rearrangement

No valid treatment for isolated myeloid sarcoma (IMS) has yet been established, and no thorough genetic examinations have been performed because of its low incidence and unique manner of development. We herein report a 34-year-old man with pancreatic IMS with t(8;21)/RUNX1-RUNX1T1 rearrangement. He...

Descripción completa

Detalles Bibliográficos
Autores principales: Tokunaga, Kenji, Yamamura, Ayako, Ueno, Shikiko, Kikukawa, Yoshitaka, Yamaguchi, Shunichiro, Hidaka, Michihiro, Matsuno, Naofumi, Kawaguchi, Tatsuya, Matsuoka, Masao, Okuno, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849554/
https://www.ncbi.nlm.nih.gov/pubmed/29151502
http://dx.doi.org/10.2169/internalmedicine.8912-17
Descripción
Sumario:No valid treatment for isolated myeloid sarcoma (IMS) has yet been established, and no thorough genetic examinations have been performed because of its low incidence and unique manner of development. We herein report a 34-year-old man with pancreatic IMS with t(8;21)/RUNX1-RUNX1T1 rearrangement. He was treated with high-dose cytarabine followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT). This is the first report of pancreatic IMS with t(8;21). Positron emission tomography/computed tomography and genetic study are useful for the diagnosis, and allo-HSCT achieved complete remission in this patient.

Ejemplares similares